Amgen, Allergan report Phase III data for Herceptin biosimilar

Amgen Inc. (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) said data from a Phase III study showed ABP 980, a biosimilar

Read the full 193 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE